Skip to main content
$6.02 -0.01 (-0.17%)
Market Cap
$397.10M
Shares
65.85M

Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Upcoming events

Date Event Type
2026-08-05 20:30 UTC Q2 2026 Evolus, Inc. Earnings Conference Call Earnings call

Recent news

Date Headline
2026-07-22 Evolus to Report Second Quarter Financial Results on August 5, 2026
2026-07-10 Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-08 Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality
2026-05-19 Evolus to Participate in The Jefferies Global Healthcare Conference
2026-05-11 Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe
2026-05-04 Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook
2026-04-14 Evolus to Report First Quarter Financial Results on May 4, 2026
2026-03-31 Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference
2026-03-20 Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-03-03 Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability<sup>1</sup> Beginning in 2026
2026-02-25 Evolus to Participate in The Leerink Partners Global Healthcare Conference
2026-02-17 Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026
2026-02-13 Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-01-09 Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue

Provides 2026 Net Revenue Guidance and Maintains Projection for Full-Year 2026 Profitability1 Preliminary Unaudited Net Revenue of $88.6 Million to $90.6 Million for the Fourth Quarter 2025, Representing 12% to 15% Growth Over the Prior Year; Company Reaffirms an Important Milestone of Positive Non-GAAP Operating Income of $5 Million to $7 Million for Q4 2025 Preliminary Unaudited Net Revenue of $295.5 Million to $297.5 Million for the Full-Year 2025, Representing 11% to 12% Growth Over the Prior Year 2026 Net Revenue Guidance of $327.0 Million to $337.0 Million, Which Represents 11% to 13% Growth from Preliminary Unaudited 2025 Results; Company Remains on Track to Achieve Sustainable Annual Profitability1 Beginning in 2026 Updates 2028 Long-Term Financial Outlook to Reflect Total Net Revenue of $450 Million to $500 Million, Representing a Three-Year CAGR of 15% to 19%, and Non-GAAP Operating Income Margins of 13% to 15% for 2028 Evolus, Inc. (NASDAQ: EOLS), a global performance

Past events

Date Event Type
2026-06-04 Jefferies Global Healthcare Conference Conference
2026-05-04 Q1 2026 Evolus, Inc. Earnings Conference Call Earnings call
2026-04-14 Needham Virtual Healthcare Conference Conference
2026-03-11 Leerink Global Healthcare Conference Conference
2026-03-03 Q4 2025 Evolus, Inc. Earnings Conference Call Earnings call
2025-11-11 Stifel 2025 Healthcare Conference Conference
2025-11-05 Q3 2025 Evolus, Inc. Earnings Conference Call Earnings call
2025-08-05 Q2 2025 Evolus, Inc. Earnings Conference Call Earnings call
2025-05-07 Q1 2025 Evolus, Inc. Earnings Conference Call Earnings call
2025-04-08 24th Annual Needham Virtual Healthcare Conference Conference
2025-03-12 Barclays 27th Annual Global Healthcare Conference Conference
2025-03-11 Leerink Partners Global Biopharma Conference Conference
2025-03-04 Q4 2024 Evolus, Inc. Earnings Conference Call Earnings call
2025-02-27 TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit Event
2024-11-19 Stifel 2024 Healthcare Conference Conference
2024-11-06 Q3 2024 Evolus, Inc. Earnings Conference Call Earnings call
2024-09-12 Evolus Investor Day Presentation
2024-08-13 Canaccord Genuity 44th Annual Growth Conference Conference
2024-07-31 Q2 2024 Evolus, Inc. Earnings Conference Call Earnings call
2024-05-21 BNPP Exane’s Aesthetics Day Conference Conference
2024-05-07 Q1 2024 Evolus, Inc. Earnings Conference Call Earnings call
2024-04-09 23rd Annual Needham Virtual Healthcare Conference Conference
2024-03-13 The Barclays 26th Annual Global Healthcare Conference Conference
2024-03-12 The Leerink Partners Global Biopharma Conference 2024 Conference
2024-03-07 Q4 2023 Evolus, Inc. Earnings Conference Call Earnings call

Source: https://investors.evolus.com/overview/default.aspx

Key facts CIK 1570562 CUSIP 30052C107 13F (30d) 24 filings 24 filers Visit website Investor relations